Skip to content
DataLookout
Menu

CGMNCT07423065

The Impact of Continuous Glucose Monitoring on Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity

StatusSuspended
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Recruitment suspended Sponsor's reason: The study has been temporarily suspended pending approval from the Slovenian Agency for Medicinal Products and Medical Devices (JAZMP). The need for this additional regulatory approval was identified following communication with JAZMP.
    • Primary completion pushed from Sep 1, 2027 to Dec 1, 2027
    • Study completion pushed from Nov 1, 2027 to Jun 1, 2028
    • Site details revised at 3 of 3 sites
  2. Notable Start date pushed from Oct 15, 2026 to Dec 15, 2026
    • Eligibility criteria expanded, about 19 words
    • Primary completion pushed from Jun 1, 2027 to Sep 1, 2027
    • Secondary endpoints: details revised at 7 of 11 entries
  3. Notable Start date: Sep 1, 2026 to Oct 15, 2026
    • Primary completion pushed from Apr 1, 2027 to Jun 1, 2027
    • Study completion pushed from Sep 1, 2027 to Nov 1, 2027
    v4
  4. Notable Recruitment openedv3 Show 4 more changesShow less
    • Start date: May 1, 2026 to Sep 1, 2026
    • Primary completion pushed from Dec 1, 2026 to Apr 1, 2027
    • Study completion pushed from Jun 1, 2027 to Sep 1, 2027
    • Site details revised at 3 of 3 sites
  5. Notable Start date: Apr 1, 2026 to May 1, 2026v2
  6. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

Change in Glycemic Variability Assessed by Coefficient of Variation from CGM
Timeframe: End of each 12-week CGM phase
Postprandial Glucose Excursions Measured by CGM
Timeframe: End of each 12-week CGM phase
Change in Mean Daily Energy Intake
Timeframe: End of each 12-week CGM phase

Secondary (11)

Change in Time in Tight Range (3.9-7.8 mmol/L) Measured by Continuous Glucose Monitoring
Change in Glycemic Variability Assessed by Standard Deviation from CGM
Change in Continuous Overall Net Glycemic Action (CONGA) from CGM
Change in Glycemic Complexity Assessed by Entropy-Based Indices from CGM
Postprandial Incremental Area Under the Curve (iAUC) Derived from CGM
Show 6 moreShow less
Adherence to Continuous Glucose Monitoring
Change in Fasting Plasma Glucose
Change in Body Weight
Change in Physical Activity Assessed by IPAQ Short Form
Change in Health Status Assessed by EQ-VAS
Change in Glycated Hemoglobin (HbA1c)

Arms and interventions

Open CGMExperimental
Blinded CGMExperimental

Devices: Continuous Glucose Monitoring (CGM)

Sites

3 sites in 1 country